These data, not only support the development of omilancor for the treatment of psoriasis, but also leverage the exploration of a new class of LANCL2-based therapeutics that target immunomodulatory mechanisms for the treatment of PsO and other inflammatory skin disorders. Here, LANCL2 is linked to inflammatory skin disease.